Corcept Therapeutics Incorporated (NASDAQ:CORT) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07 Submission of Matters to a Vote of Security Holders

On May24, 2017, we held our annual meeting of stockholders to
consider and vote on proposals: 1) to elect seven directors to
hold office until our 2018 annual meeting of stockholders and
until their successors are elected and qualified, 2) to ratify
the appointment of Ernst Young LLP as our independent registered
public accounting firm for the fiscal year ending December31,
2017, 3) to approve, by non-binding advisory vote, the
compensation of our named executive officers, and 4) to
recommend, by non-binding advisory vote, the frequency of the
advisory vote on the compensation of our named executive
officers.

A total of 113,112,210 shares of Corcept Therapeutics
Incorporated common stock held by stockholders of record at the
close of business on March31, 2017 were entitled to vote at the
annual meeting. The total number of shares voted at the annual
meeting was 108,840,308. The voting on the four matters is set
forth below:

Proposal 1 Election of Directors. The following directors were
elected to serve until our 2018 annual meeting of stockholders
and until their successors are elected.

Proposal 2 To ratify the appointment of Ernst Young LLP as our
independent registered public accounting firm for the fiscal year
ending December31, 2017.

Proposal 3 To approve, by non-binding advisory vote, the
compensation of our named executive officers.

Proposal 4 To recommend, by non-binding advisory vote, the
frequency of the advisory vote on the compensation of our named
executive officers.

Based on the recommendation of our Board of Directors in the
proxy statement for the annual meeting and the voting results
with respect to the non-binding advisory vote to determine the
frequency of advisory votes on the compensation of our named
executive officers, our Board of Directors determined that the
company will hold an advisory vote on compensation of our named
executive officers every three years until the next frequency
advisory vote.

About Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). It has also discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. It has begun pre-clinical and clinical development of its lead compounds from these series.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Recent Trading Information

Corcept Therapeutics Incorporated (NASDAQ:CORT) closed its last trading session down -0.80 at 11.49 with 1,264,095 shares trading hands.